Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susumu Kobayashi, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R01CA240257 (KOBAYASHI, SUSUMU) Feb 7, 2020 - Jan 31, 2025
    NIH
    Role of KAT5 in lung cancer
    Role: Principal Investigator
  2. R21CA178301 (KOBAYASHI, SUSUMU) Dec 9, 2014 - Nov 30, 2017
    NIH
    Emergence of drug resistant mutations in lung cancer
    Role: Principal Investigator
  3. R01CA169259 (KOBAYASHI, SUSUMU) Mar 6, 2013 - Feb 28, 2019
    NIH
    Overcoming resistance to tyrosine kinase inhibitors in lung cancer
    Role: Principal Investigator
  4. R00CA126026 (KOBAYASHI, SUSUMU) Jul 1, 2007 - Mar 31, 2013
    NIH
    Role of EGFR mutations and new therapeutics in lung cancer
    Role: Principal Investigator
  5. K99CA126026 (KOBAYASHI, SUSUMU) Jul 1, 2007 - Jun 30, 2009
    NIH
    Role of EGFR mutations and new therapeutics in lung cancer
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi IS, Sun J, Politi K, Levantini E, Zhang W, Kobayashi SS, Zhang WC. An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1. Br J Cancer. 2023 Feb 21. PMID: 36810913.
    Citations:    Fields:    
  2. Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023 Feb 13; 41(2):340-355.e6. PMID: 36787696.
    Citations:    Fields:    Translation:HumansCells
  3. Oguchi K, Araki H, Tsuji S, Nakamura M, Miura A, Funabashi K, Osada A, Tanaka S, Suzuki T, Kobayashi SS, Mizuarai S. TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations. Cancer Sci. 2023 Feb; 114(2):654-664. PMID: 36282234; PMCID: PMC9899605.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  4. de Miranda LBL, Lima K, Coelho-Silva JL, Traina F, Kobayashi SS, Machado-Neto JA. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells. Sci Rep. 2022 10 12; 12(1):17092. PMID: 36224313; PMCID: PMC9556623.
    Citations:    Fields:    Translation:HumansCells
  5. Fernandes de Oliveira Costa A, Olops Marani L, Mantello Bianco T, Queiroz Arantes A, Aparecida Lopes I, Antonio Pereira-Martins D, Carvalho Palma L, Santos Scheucher P, Lilian Dos Santos Schiavinato J, Sarri Binelli L, Araújo Silva C, Kobayashi SS, Agostinho Machado-Neto J, Magalhães Rego E, Samuel Welner R, Lobo de Figueiredo-Pontes L. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Front Immunol. 2022; 13:768592. PMID: 36211444; PMCID: PMC9539129.
    Citations:    Fields:    Translation:HumansAnimalsCells
  6. Kobayashi IS, Viray H, Rangachari D, Kobayashi SS, Costa DB. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells. 2021 12 17; 10(12). PMID: 34944068; PMCID: PMC8700411.
    Citations:    Fields:    Translation:HumansAnimalsCells
  7. Takei H, Coelho-Silva JL, Tavares Leal C, Queiroz Arantes Rocha A, Mantello Bianco T, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima K, Machado-Neto JA, Kobayashi SS, Lobo de Figueiredo-Pontes L. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Sci. 2022 Feb; 113(2):597-608. PMID: 34808021; PMCID: PMC8819353.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  8. Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 2021 12; 600(7888):319-323. PMID: 34819663; PMCID: PMC8687755.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  9. Ummarino S, Hausman C, Gaggi G, Rinaldi L, Bassal MA, Zhang Y, Seelam AJ, Kobayashi IS, Borchiellini M, Ebralidze AK, Ghinassi B, Trinh BQ, Kobayashi SS, Di Ruscio A. NAD Modulates DNA Methylation and Cell Differentiation. Cells. 2021 11 02; 10(11). PMID: 34831209; PMCID: PMC8616462.
    Citations: 1     Fields:    Translation:HumansCells
  10. Trinh BQ, Ummarino S, Zhang Y, Ebralidze AK, Bassal MA, Nguyen TM, Heller G, Coffey R, Tenen DE, van der Kouwe E, Fabiani E, Gurnari C, Wu CS, Angarica VE, Yang H, Chen S, Zhang H, Thurm AR, Marchi F, Levantini E, Staber PB, Zhang P, Voso MT, Pandolfi PP, Kobayashi SS, Chai L, Di Ruscio A, Tenen DG. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021 10 14; 138(15):1331-1344. PMID: 33971010; PMCID: PMC8525335.
    Citations: 4     Fields:    Translation:HumansCells
  11. Kashima Y, Shibahara D, Suzuki A, Muto K, Kobayashi IS, Plotnick D, Udagawa H, Izumi H, Shibata Y, Tanaka K, Fujii M, Ohashi A, Seki M, Goto K, Tsuchihara K, Suzuki Y, Kobayashi SS. Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Res. 2021 09 15; 81(18):4835-4848. PMID: 34247147; PMCID: PMC8448980.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  12. Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021 07 15; 81(14):3916-3929. PMID: 34083250.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  13. Yoda T, Furuta M, Tsutsumi T, Ikeda S, Yukizawa S, Arai S, Morita A, Yamatoya K, Nakata K, Tomoshige S, Ohgane K, Furuyama Y, Sakaguchi K, Sugawara F, Kobayashi S, Ikekita M, Kuramochi K. Epo-C12 inhibits peroxiredoxin 1 peroxidase activity. Bioorg Med Chem. 2021 07 01; 41:116203. PMID: 34015702.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  14. Piper-Vallillo AJ, Kobayashi SS, Costa DB. Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations. JTO Clin Res Rep. 2021 Mar; 2(3):100133. PMID: 34589996.
    Citations:    
  15. Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y. HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs. Thorac Cancer. 2021 03; 12(5):631-642. PMID: 33471376.
    Citations: 2     Fields:    Translation:HumansAnimals
  16. Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS, Mukohara T. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep. 2020 12 10; 10(1):21762. PMID: 33303839; PMCID: PMC7729878.
    Citations: 10     Fields:    Translation:HumansCells
  17. Vasconcelos PENS, Kobayashi IS, Kobayashi SS, Costa DB. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. JTO Clin Res Rep. 2021 Mar; 2(3). PMID: 33728415; PMCID: PMC7959160.
    Citations: 7     
  18. Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist. 2021 04; 26(4):281-287. PMID: 32969527; PMCID: PMC8018319.
    Citations: 4     Fields:    Translation:Humans
  19. Sakamoto Y, Xu L, Seki M, Yokoyama TT, Kasahara M, Kashima Y, Ohashi A, Shimada Y, Motoi N, Tsuchihara K, Kobayashi SS, Kohno T, Shiraishi Y, Suzuki A, Suzuki Y. Long-read sequencing for non-small-cell lung cancer genomes. Genome Res. 2020 09; 30(9):1243-1257. PMID: 32887687.
    Citations: 9     Fields:    Translation:HumansCells
  20. Piper-Vallillo AJ, Halbert BT, Rangachari D, Kobayashi SS, Costa DB. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer. JTO Clin Res Rep. 2020 Nov 01; 1(4):100071. PMID: 33225315; PMCID: PMC7305494.
    Citations: 8     
  21. Takei H, Fukuda H, Pan G, Yamazaki H, Matsumoto T, Kazuma Y, Fujii M, Nakayama S, Kobayashi IS, Shindo K, Yamashita R, Shirakawa K, Takaori-Kondo A, Kobayashi SS. Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator. Int J Hematol. 2020 Sep; 112(3):395-408. PMID: 32533515.
    Citations: 1     Fields:    Translation:HumansCells
  22. Vasconcelos PENS, Gergis C, Viray H, Varkaris A, Fujii M, Rangachari D, VanderLaan PA, Kobayashi IS, Kobayashi SS, Costa DB. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2020 Sep; 1(3). PMID: 34104899; PMCID: PMC8183979.
    Citations: 10     
  23. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277. PMID: 32358026.
    Citations:    Fields:    
  24. Tanaka A, Kobayashi S, Xiao M, Inoue D. [Understanding and therapeutic targeting of aberrant mRNA splicing mechanisms in oncogenesis]. Rinsho Ketsueki. 2020; 61(6):643-650. PMID: 32624538.
    Citations: 1     Fields:    Translation:HumansCells
  25. Takenaka T, Nakai S, Katayama M, Hirano M, Ueno N, Noguchi K, Takatani-Nakase T, Fujii I, Kobayashi SS, Nakase I. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. Int J Pharm. 2019 Dec 15; 572:118762. PMID: 31610280.
    Citations: 11     Fields:    Translation:HumansCells
  26. Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res. 2019 11; 17(11):2233-2243. PMID: 31467113; PMCID: PMC6872223.
    Citations: 15     Fields:    Translation:HumansCells
  27. Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019 11; 14(11):1995-2002. PMID: 31377341; PMCID: PMC6823139.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  28. Radhakrishnan S, Syed R, Takei H, Kobayashi IS, Nakamura E, Sultana F, Kamal A, Tenen DG, Kobayashi SS. Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation. Bioorg Med Chem Lett. 2019 08 15; 29(16):2286-2289. PMID: 31278031.
    Citations:    Fields:    Translation:HumansCells
  29. Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 2019 05 14; 116(20):10025-10030. PMID: 31043566; PMCID: PMC6525482.
    Citations: 11     Fields:    Translation:HumansCells
  30. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555. PMID: 30154228; PMCID: PMC6295229.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  31. Sridhar R, Takei H, Syed R, Kobayashi IS, Hui LB, Kamal A, Tenen DG, Kobayashi SS. Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPa. Molecules. 2018 Aug 03; 23(8). PMID: 30081475.
    Citations: 2     Fields:    Translation:HumansCells
  32. Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 01; 14(1):e1-e3. PMID: 29981924.
    Citations: 3     Fields:    Translation:Humans
  33. Takei H, Kobayashi SS. Targeting transcription factors in acute myeloid leukemia. Int J Hematol. 2019 Jan; 109(1):28-34. PMID: 29956082.
    Citations: 15     Fields:    Translation:Humans
  34. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95. PMID: 29413057.
    Citations: 16     Fields:    Translation:Humans
  35. Kobayashi SS, Takei H. [Transcription factor-based therapies for acute myeloid leukemia]. Rinsho Ketsueki. 2018; 59(7):922-931. PMID: 30078804.
    Citations: 1     Fields:    Translation:Humans
  36. Gonzalez D, Luyten A, Bartholdy B, Zhou Q, Kardosova M, Ebralidze A, Swanson KD, Radomska HS, Zhang P, Kobayashi SS, Welner RS, Levantini E, Steidl U, Chong G, Collombet S, Choi MH, Friedman AD, Scott LM, Alberich-Jorda M, Tenen DG. ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPa. J Biol Chem. 2017 11 17; 292(46):18924-18936. PMID: 28900037.
    Citations: 8     Fields:    Translation:HumansCells
  37. Takenaka T, Katayama M, Sugiyama A, Hagiwara M, Fujii I, Takatani-Nakase T, Kobayashi SS, Nakase I. Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density. Anticancer Res. 2017 09; 37(9):4779-4788. PMID: 28870896.
    Citations: 4     Fields:    Translation:HumansCells
  38. Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177. PMID: 28611010.
    Citations: 7     Fields:    Translation:Humans
  39. Takahashi Y, Sano R, Yasuda A, Kuboya E, Takahashi K, Kubo R, Kominato Y, Takei H, Kobayashi S, Shimada T, Awata S, Tokue H, Hirasawa S. Postmortem computed tomography evaluation of fatal gas embolism due to connection of an intravenous cannula to an oxygen supply. Leg Med (Tokyo). 2017 Jul; 27:1-4. PMID: 28577412.
    Citations: 3     Fields:    Translation:Humans
  40. Jin J, Zhan P, Katoh M, Kobayashi SS, Phan K, Qian H, Li H, Wang X, Wang X, Song Y. Prognostic significance of ß-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017 Feb; 6(1):97-108. PMID: 28331830; PMCID: PMC5344847.
    Citations: 10     
  41. VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21. PMID: 28285689.
    Citations: 80     Fields:    Translation:Humans
  42. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883. PMID: 28104537.
    Citations: 57     Fields:    Translation:Humans
  43. Sidthipong K, Ma J, Yu WL, Wang YF, Kobayashi S, Kishino S, Koide N, Yokochi T, Kato K, Okada S, Umezawa K. Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-?B inhibitor. Bioorg Med Chem Lett. 2017 02 01; 27(3):562-566. PMID: 28003138.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  44. Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, Wajapeyee N. Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Rep. 2016 07 12; 16(2):457-471. PMID: 27346347.
    Citations: 24     Fields:    Translation:HumansCells
  45. Kobayashi SS, Vali S, Kumar A, Singh N, Abbasi T, Sayeski PP. Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. Oncotarget. 2016 Jun 14; 7(24):35989-36001. PMID: 27056884.
    Citations: 2     Fields:    Translation:HumansCells
  46. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22. PMID: 27565908.
    Citations: 8     Fields:    Translation:HumansCells
  47. Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, Kobayashi SS. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016 06; 11(6):918-23. PMID: 26964772.
    Citations: 18     Fields:    Translation:HumansCells
  48. Costa DB, Kobayashi SS. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res. 2015 Dec; 4(6):809-15. PMID: 26798593; PMCID: PMC4700227.
    Citations: 28     
  49. Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015 Nov 17; 6(36):38789-803. PMID: 26515464; PMCID: PMC4770737.
    Citations: 62     Fields:    Translation:HumansCells
  50. Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74. PMID: 26791794.
    Citations: 33     Fields:    Translation:HumansCells
  51. Radomska HS, Jernigan F, Nakayama S, Jorge SE, Sun L, Tenen DG, Kobayashi SS. A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. J Biomol Screen. 2015 Oct; 20(9):1150-9. PMID: 26109609.
    Citations: 9     Fields:    Translation:HumansCells
  52. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9. PMID: 25922291.
    Citations: 5     Fields:    Translation:Humans
  53. Cai Y, Hirata A, Nakayama S, VanderLaan PA, Levantini E, Yamamoto M, Hirai H, Wong KK, Costa DB, Watanabe H, Kobayashi SS. CCAAT/enhancer binding protein ß is dispensable for development of lung adenocarcinoma. PLoS One. 2015; 10(3):e0120647. PMID: 25767874.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  54. Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, Tan AJ, Yamaguchi N, Yasuda H, Li D, Soejima K, Soo RA, Costa DB, Wong KK, Kobayashi SS. ß-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 2014 Oct 15; 74(20):5891-902. PMID: 25164010.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  55. de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):248-53. PMID: 24419423.
    Citations: 6     Fields:    Translation:HumansCells
  56. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177. PMID: 24353160; PMCID: PMC3954775.
    Citations: 174     Fields:    Translation:HumansCells
  57. Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer. 2014 Jan; 83(1):37-43. PMID: 24199682.
    Citations: 40     Fields:    Translation:HumansCells
  58. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013 Jan; 8(1):45-51. PMID: 23242437.
    Citations: 64     Fields:    Translation:HumansCells
  59. Ackerman A, Goldstein MA, Kobayashi S, Costa DB. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):e19-20. PMID: 22982663.
    Citations: 11     Fields:    Translation:Humans
  60. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012 Jul; 7(7):1086-90. PMID: 22617245.
    Citations: 60     Fields:    Translation:HumansCells
  61. Miyano Y, Tsukuda S, Sakimoto I, Takeuchi R, Shimura S, Takahashi N, Kusayanagi T, Takakusagi Y, Okado M, Matsumoto Y, Takakusagi K, Takeuchi T, Kamisuki S, Nakazaki A, Ohta K, Miura M, Kuramochi K, Mizushina Y, Kobayashi S, Sugawara F, Sakaguchi K. Exploration of the binding proteins of perfluorooctane sulfonate by a T7 phage display screen. Bioorg Med Chem. 2012 Jul 01; 20(13):3985-90. PMID: 22658539.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  62. Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, Sukhatme VP. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol. 2012 Apr; 227(4):1709-20. PMID: 21688263.
    Citations: 57     Fields:    Translation:HumansAnimalsCells
  63. Costa DB, Kobayashi S. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol. 2012 Mar; 7(3):623-5. PMID: 22334013.
    Citations: 8     Fields:    Translation:Humans
  64. Basseres DS, D'Alò F, Yeap BY, Löwenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7. PMID: 22341411.
    Citations: 20     Fields:    Translation:HumansCells
  65. Nguyen KS, Sanford RA, Huberman MS, Goldstein MA, McDonald DM, Farquhar M, Gangadharan SP, Kent MS, Michaud G, Majid A, Berman SM, Aronovitz JA, Nedea EA, Boiselle PM, Cohen DW, Kobayashi S, Costa DB. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract. 2012 Jan; 8(1):57-62. PMID: 22548013.
    Citations: 2     Fields:    
  66. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012 Jan; 13(1):e23-31. PMID: 21764376.
    Citations: 221     Fields:    Translation:HumansAnimalsCells
  67. Takami M, Takakusagi Y, Kuramochi K, Tsukuda S, Aoki S, Morohashi K, Ohta K, Kobayashi S, Sakaguchi K, Sugawara F. A screening of a library of T7 phage-displayed peptide identifies E2F-4 as an etoposide-binding protein. Molecules. 2011 May 24; 16(5):4278-94. PMID: 21610657.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  68. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011 May 20; 29(15):e443-5. PMID: 21422405.
    Citations: 229     Fields:    Translation:Humans
  69. Li-Wan-Po A, Farndon PA, Kobayashi S, Mitsudomi T, Potter VA. The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Ann Pharmacother. 2011 Feb; 45(2):263-75. PMID: 21304034.
    Citations:    Fields:    Translation:Humans
  70. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010 Nov; 1(7):497-514. PMID: 21165163.
    Citations: 79     Fields:    Translation:HumansAnimals
  71. Gupte R, Siddam A, Lu Y, Li W, Fujiwara Y, Panupinthu N, Pham TC, Baker DL, Parrill AL, Gotoh M, Murakami-Murofushi K, Kobayashi S, Mills GB, Tigyi G, Miller DD. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett. 2010 Dec 15; 20(24):7525-8. PMID: 21051230; PMCID: PMC3040411.
    Citations: 6     Fields:    Translation:Animals
  72. Kuramochi K, Saito F, Nakazaki A, Takeuchi T, Tsubaki K, Sugawara F, Kobayashi S. Synthesis of pseudodeflectusin and ustusorane C: structural revision of aspergione a and B. Biosci Biotechnol Biochem. 2010; 74(8):1635-40. PMID: 20699584.
    Citations: 3     Fields:    
  73. Costa DB, Kobayashi S, Yeo WL, Hamada A. Serum concentrations of Erlotinib at a dose of 25 mg daily. J Thorac Oncol. 2010 Aug; 5(8):1311-2. PMID: 20661096.
    Citations: 4     Fields:    Translation:Humans
  74. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53. PMID: 20512075.
    Citations: 37     Fields:    Translation:HumansCells
  75. O'Brien KB, Alberich-Jordà M, Yadav N, Kocher O, Diruscio A, Ebralidze A, Levantini E, Sng NJ, Bhasin M, Caron T, Kim D, Steidl U, Huang G, Halmos B, Rodig SJ, Bedford MT, Tenen DG, Kobayashi S. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010 Jul; 137(13):2147-56. PMID: 20530543.
    Citations: 33     Fields:    Translation:AnimalsCells
  76. Will B, Siddiqi T, Jordà MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010 Apr 08; 115(14):2901-9. PMID: 20160166; PMCID: PMC2854433.
    Citations: 28     Fields:    Translation:HumansCells
  77. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, Halmos B. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis. 2010 Apr; 31(4):577-86. PMID: 20097731; PMCID: PMC2847094.
    Citations: 84     Fields:    Translation:HumansCells
  78. Akiba T, Marushima H, Kobayashi S, Morikawa T. Video-assisted thoracic surgery for recurrent primary spontaneous pneumothorax in reoperated chests. Surg Today. 2009; 39(11):944-6. PMID: 19882315.
    Citations: 2     Fields:    Translation:Humans
  79. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53. PMID: 19667264.
    Citations: 711     Fields:    Translation:Humans
  80. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009 Jul; 10(4):281-9. PMID: 19632948; PMCID: PMC2758558.
    Citations: 184     Fields:    Translation:Humans
  81. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94. PMID: 19447865; PMCID: PMC2893040.
    Citations: 125     Fields:    Translation:HumansAnimalsCells
  82. Costa DB, Kobayashi S. Gefitinib plus docetaxel in non-small-cell lung cancer. Lancet. 2009 Feb 14; 373(9663):541; author reply 542. PMID: 19217979.
    Citations:    Fields:    Translation:Humans
  83. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7. PMID: 18981003; PMCID: PMC2596582.
    Citations: 70     Fields:    Translation:Humans
  84. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38. PMID: 18632637; PMCID: PMC3272303.
    Citations: 77     Fields:    Translation:AnimalsCells
  85. Cha HC, Oak NR, Kang S, Tran TA, Kobayashi S, Chiang SH, Tenen DG, MacDougald OA. Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. J Biol Chem. 2008 Jun 27; 283(26):18002-11. PMID: 18408001.
    Citations: 10     Fields:    Translation:AnimalsCells
  86. Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008 Mar 01; 26(7):1182-4; author reply 1184-6. PMID: 18309959.
    Citations: 50     Fields:    Translation:Humans
  87. Costa DB, Kobayashi S. Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations. J Clin Oncol. 2008 Feb 01; 26(4):686. PMID: 18235134.
    Citations: 1     Fields:    Translation:Humans
  88. Costa DB, Kobayashi S, Schumer ST. Erlotinib-associated alopecia in a lung cancer patient. J Thorac Oncol. 2007 Dec; 2(12):1136-8. PMID: 18090591.
    Citations: 2     Fields:    Translation:Humans
  89. Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007 Nov 01; 67(21):10417-27. PMID: 17974985.
    Citations: 28     Fields:    Translation:HumansCells
  90. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680. PMID: 17973572.
    Citations: 238     Fields:    Translation:HumansCells
  91. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep; 117(9):2611-20. PMID: 17694175; PMCID: PMC1937499.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  92. Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Müller-Tidow C, Serve H, Tenen DG. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007 Nov 15; 110(10):3695-705. PMID: 17671235; PMCID: PMC2077317.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  93. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103. PMID: 17610986.
    Citations: 64     Fields:    Translation:Humans
  94. Costa DB, Kobayashi S. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? Br J Cancer. 2007 Jan 29; 96(2):399; author reply 400. PMID: 17224926; PMCID: PMC2359997.
    Citations: 3     Fields:    Translation:Humans
  95. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98. PMID: 17145885.
    Citations: 66     Fields:    Translation:HumansAnimalsCells
  96. Kubo S, Levantini E, Kobayashi S, Kocher O, Halmos B, Tenen DG, Takahashi M. Three-dimensional magnetic resonance microscopy of pulmonary solitary tumors in transgenic mice. Magn Reson Med. 2006 Sep; 56(3):698-703. PMID: 16902979.
    Citations: 6     Fields:    Translation:Animals
  97. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95. PMID: 16730237.
    Citations: 181     Fields:    Translation:HumansAnimalsCells
  98. Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, Kutok JL, Gilliland DG, Krauter J, Tenen DG. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6338-43. PMID: 16606850.
    Citations: 26     Fields:    Translation:AnimalsCells
  99. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94. PMID: 16106023.
    Citations: 109     Fields:    Translation:HumansCells
  100. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15; 65(16):7096-101. PMID: 16103058.
    Citations: 84     Fields:    Translation:AnimalsCells
  101. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92. PMID: 15728811.
    Citations: 1527     Fields:    Translation:HumansCells
  102. Kobayashi S, Yamashita K, Takeoka T, Ohtsuki T, Suzuki Y, Takahashi R, Yamamoto K, Kaufmann SH, Uchiyama T, Sasada M, Takahashi A. Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. J Biol Chem. 2002 Sep 13; 277(37):33968-77. PMID: 12121983.
    Citations: 32     Fields:    Translation:HumansCells
  103. Makoto O, Takeda A, Ting-Leig L, Shinnichi O, Hisahiro M, Yutaka F, Yoshihiro N, Kobayashi S, Gunji Y, Suzuki T, Takenori O, Hideaki S. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep. 2002 Jan-Feb; 9(1):23-8. PMID: 11748450.
    Citations: 5     Fields:    Translation:Humans
  104. Yamashita K, Takahashi A, Kobayashi S, Hirata H, Mesner PW, Kaufmann SH, Yonehara S, Yamamoto K, Uchiyama T, Sasada M. Caspases mediate tumor necrosis factor-alpha-induced neutrophil apoptosis and downregulation of reactive oxygen production. Blood. 1999 Jan 15; 93(2):674-85. PMID: 9885230.
    Citations: 16     Fields:    Translation:HumansCells
  105. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K, Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 1998 Feb 16; 187(4):587-600. PMID: 9463409; PMCID: PMC2212161.
    Citations: 76     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Kobayashi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (438)
Explore
_
Co-Authors (70)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.